Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Rutkowski, Piotr; Kamińska, Janina; Kowalska, M; Ruka, W.; Steffen, Jan

doi:10.1002/ijc.10496

Cited by 85 publications

(78 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings suggest that measurement of levels of angiogenic factors may provide prognostic information. This is consistent with earlier studies in sarcoma and other diseases in which elevated VEGF correlated with higher stage and/or poor outcome (20,51), although in one study of synovial sarcoma a correlation was not observed (53). It remains to be seen whether urinary VEGF levels will useful for predicting or monitoring responses to therapy (22).…”

Section: Discussionsupporting

confidence: 89%

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

Heymach¹,

Desai²,

Manola

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: SU5416 (semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor-2 and KIT receptor tyrosine kinases. This Phase II study was conducted to investigate the safety and efficacy of SU5416 for patients with soft tissue sarcomas.Experimental Design: Thirteen patients with locally advanced or metastatic soft tissue sarcomas were treated with SU5416 via intravenous infusion at a dose of 145 mg/m 2 twice weekly. In selected cases tumor biopsies were taken before and after 2 months of treatment.Results: The median progression-free survival was 1.8 months. Median overall survival was 22.8 months. No objective tumor responses were observed. There was evidence of shorter survival among patients with high baseline urine VEGF levels (P ‫؍‬ 0.04). No grade 4 toxicities were observed.The most common grade 3 toxicities were headache and thrombosis. Other less serious toxicities included fatigue, nausea, and abdominal pain. The median systolic blood pressure increased from 118 mmHg at baseline to 133 after 1 month of treatment (P ‫؍‬ 0.01). Post-treatment tumor biopsies showed no significant decreases in VEGF receptor phosphorylation compared with baseline in 3 evaluable patients. One patient with gastrointestinal stromal tumor who had rapid progression during SU5416 treatment was subsequently treated with another KIT inhibitor, imatinib mesylate, and had a partial response lasting >36 months.Conclusions: SU5416 was relatively well tolerated but did not demonstrate significant antitumor activity against advanced soft tissue sarcoma. Correlative studies suggest that VEGF receptor or KIT inhibition was incomplete in at least some cases, providing a possible explanation for the observed lack of activity.

show abstract

Section: Discussionsupporting

confidence: 89%

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

Heymach¹,

Desai²,

Manola

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Serological study showed that IL-6 has a positive correlation with the progression of various soft tissue sarcomas including MFH. 37 In our recent study, CRP, which directly reflects IL-6, proved to be significantly associated with the malignancy grade, tumor size, and histological subtypes of MFH. 6 These findings indicate that IL-6 may be responsible for its biological behavior; tumor progression, proliferation, and morphology.…”

Section: Discussionmentioning

confidence: 85%

Interleukin-6/Soluble Interleukin-6 Receptor Signaling Attenuates Proliferation and Invasion, and Induces Morphological Changes of a Newly Established Pleomorphic Malignant Fibrous Histiocytoma Cell Line

Nakanishi

Yoshioka

Joyama

et al. 2004

The American Journal of Pathology

View full text Add to dashboard Cite

Pleomorphic malignant fibrous histiocytoma (MFH)is occasionally associated with inflammatory paraneoplastic syndrome (PNS). Recently, we reported that interleukin (IL)-6, one of the candidate cytokines, which induces such systemic inflammatory reaction, may be a tumor-associated factor involved in the pathogenesis and its clinical manifestations of MFH. In the local microenvironment, tumor-induced inflammatory reaction may play a role favoring tumor progression. To clarify the biological relevance of IL-6 in MFH, we established a human MFH cell line, named MIPS-2, derived from a resected specimen of a patient presenting with PNS. In this patient, the serum IL-6 level ran parallel to the disease course: elevated serum IL-6 concentration normalized immediately after radical surgery, and re-elevation occurred on tumor recurrence. MIPS-2 presented pleomorphic appearance, severe nuclear abnormalities with prominent nucleoli, and tumorigenesis in nude mice. MIPS-2 expressed IL-6, IL-6 receptor (IL-6R

show abstract

“…Reports in melanoma (13)(14)(15), non-small-cell lung cancer (NSCLC; refs. 16,17), prostate cancer (18), esophageal squamous cell carcinoma (19), soft sarcoma (20) and bone sarcoma (21), renal cell carcinoma (RCC; ref. 22), urothelial tumors (23,24), hepatocellular carcinoma (HCC; refs.…”

Section: Introductionmentioning

confidence: 99%

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Sanmamed

Carranza-Rua

Alfaro

et al. 2014

Clinical Cancer Research

217

158

View full text Add to dashboard Cite

Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden.Experimental Design: IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples from 126 patients with cancer. We correlated IL8 serum levels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis.Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n ¼ 16), renal cell carcinoma (RCC; n ¼ 23), non-small cell lung cancer (NSCLC; n ¼ 21), or hepatocellular carcinoma (HCC; n ¼ 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n ¼ 16; RCC, n ¼ 23; HCC, n ¼ 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n ¼ 16) and immunomodulatory monoclonal antibodies (melanoma, n ¼ 8). IL8 concentrations in urine (n ¼ 18) were mainly elevated in tumors with direct contact with the urinary tract.Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer.

show abstract

Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Cited by 85 publications

References 68 publications

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

Interleukin-6/Soluble Interleukin-6 Receptor Signaling Attenuates Proliferation and Invasion, and Induces Morphological Changes of a Newly Established Pleomorphic Malignant Fibrous Histiocytoma Cell Line

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Contact Info

Product

Resources

About